Tobias Klatte1, Evanguelos Xylinas2, Malte Rieken3, Morgan Rouprêt4, Harun Fajkovic1, Christian Seitz1, Pierre I Karakiewicz5, Yair Lotan6, Marko Babjuk7, Michela de Martino1, Shahrokh F Shariat8. 1. Department of Urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria. 2. Department of Urology, Weill Cornell Medical College, Presbyterian Hospital, New York, NY; Department of Urology, Cochin Hospital, APHP, Paris Descartes University, Paris, France. 3. Department of Urology, Weill Cornell Medical College, Presbyterian Hospital, New York, NY; Department of Urology, University Hospital Basel, Basel, Switzerland. 4. Department of Urology, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique Hopitaux de Paris, Faculty of Medicine Pierre et Marie Curie, Institut Universitaire de Cancérologie GRC5, University Paris 6, Paris, France. 5. Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Quebec, Canada. 6. Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. 7. Department of Urology, Hospital Motol, Second Faculty of Medicine, Prague, Czech Republic. 8. Department of Urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria; Department of Urology, Weill Cornell Medical College, Presbyterian Hospital, New York, NY. Electronic address: sfshariat@gmail.com.
Abstract
OBJECTIVE: ABO blood type is an inherited characteristic that has been associated with the prognosis of several malignancies, but there is little evidence in urothelial carcinoma of the bladder (UCB). The purpose of this study was to evaluate the effect of ABO blood type on mortality in patients with UCB treated with radical cystectomy (RC). METHODS: Multi-institutional data from 7,906 patients with UCB treated with RC between 1979 and 2012 were retrospectively analyzed. The effect of ABO blood type on UCB-related mortality was evaluated with univariable and multivariable competing-risks regression models. RESULTS: ABO blood type was O in 3,728 (47%), A in 2,748 (35%), B in 888 (11%), and AB in 532 (7%) patients. Blood type B was associated with a greater likelihood of lymphovascular invasion (P = 0.010) and positive soft tissue margins (P = 0.008). The median follow-up was 41 months. The 5-year cumulative UCB-related mortality rates for blood type O, A, B, and AB were 29.5%, 30.5%, 33.2%, and 25.8%, respectively. In univariable competing-risks regression, patients with blood type B had worse UCB-related mortality than those with blood type O (P = 0.026) and AB (P = 0.020). In multivariable analysis, however, blood type lost its statistical significance. CONCLUSIONS: Among patients treated with RC, ABO blood type is associated with a statistically significant but clinically insignificant difference in UCB-related mortality. This association was not present in multivariable analysis. Our data therefore suggest no relevant association of ABO blood type with UCB-related prognosis.
OBJECTIVE:ABO blood type is an inherited characteristic that has been associated with the prognosis of several malignancies, but there is little evidence in urothelial carcinoma of the bladder (UCB). The purpose of this study was to evaluate the effect of ABO blood type on mortality in patients with UCB treated with radical cystectomy (RC). METHODS: Multi-institutional data from 7,906 patients with UCB treated with RC between 1979 and 2012 were retrospectively analyzed. The effect of ABO blood type on UCB-related mortality was evaluated with univariable and multivariable competing-risks regression models. RESULTS:ABO blood type was O in 3,728 (47%), A in 2,748 (35%), B in 888 (11%), and AB in 532 (7%) patients. Blood type B was associated with a greater likelihood of lymphovascular invasion (P = 0.010) and positive soft tissue margins (P = 0.008). The median follow-up was 41 months. The 5-year cumulative UCB-related mortality rates for blood type O, A, B, and AB were 29.5%, 30.5%, 33.2%, and 25.8%, respectively. In univariable competing-risks regression, patients with blood type B had worse UCB-related mortality than those with blood type O (P = 0.026) and AB (P = 0.020). In multivariable analysis, however, blood type lost its statistical significance. CONCLUSIONS: Among patients treated with RC, ABO blood type is associated with a statistically significant but clinically insignificant difference in UCB-related mortality. This association was not present in multivariable analysis. Our data therefore suggest no relevant association of ABO blood type with UCB-related prognosis.
Authors: Oliver Engel; Armin Soave; Sven Peine; Luis A Kluth; Marianne Schmid; Shahrokh F Shariat; Roland Dahlem; Margit Fisch; Michael Rink Journal: World J Urol Date: 2015-03-18 Impact factor: 4.226
Authors: Aurélie Mbeutcha; Ilaria Lucca; Vitaly Margulis; Jose A Karam; Christopher G Wood; Michela de Martino; Romain Mathieu; Andrea Haitel; Evanguelos Xylinas; Luis Kluth; Morgan Rouprêt; Pierre I Karakiewicz; Alberto Briganti; Michael Rink; Malte Rieken; Alon Z Weizer; Jay D Raman; Nathalie Rioux-Leclecq; Christian Bolenz; Karim Bensalah; Yair Lotan; Christian Seitz; Mesut Remzi; Shahrokh F Shariat; Tobias Klatte Journal: World J Urol Date: 2015-12-11 Impact factor: 4.226